Cancer Family
Breast Neoplasm
CI-CAN-00000007Explore in graph →
Non-malignant2,894 active trials43 approved drugs310 evidence items
- NCIt
- C2910
- OncoTree
- BNNOS
- MeSH
- D000069584
- MeSH
- D001943
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000007Explore in graph →
Clinical trials
13,867 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01275677 | Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer | completed | Phase 3 | 3,270 | National Cancer Institute (NCI)NIH | 4 | Jul 14, 2025 | clinicaltrials |
| NCT01354522 | TAC Versus TCX as Adjuvant Treatment for High-risk Her2-Negative Breast Cancer | completed | Phase 3 | 204 | Peking Union Medical College HospitalOTHER | 1 | Jun 15, 2025 | clinicaltrials |
| NCT00769379 | Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy | completed | Phase 3 | 2,014 | National Cancer Institute (NCI)NIH | 4 | Jun 12, 2025 | clinicaltrials |
| NCT00253422 | Study of Faslodex +/- Concomitant Arimidex v Exemestane Following Progression on Non-steroidal Aromatase Inhibitors(SoFEA) | completed | Phase 3 | 698 | Institute of Cancer Research, United KingdomOTHER | 1 | Jun 4, 2025 | clinicaltrials |
| NCT01526369 | A Randomized Study of TH Versus THL in First Line Treatment of HER2-positive Metastatic Breast Cancer(TH V THL) | completed | Phase 3 | 75 | Cancer Trials IrelandNETWORK | 8 | May 9, 2025 | clinicaltrials |
| NCT00265759 | Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer | completed | Phase 3 | 622 | Alliance for Clinical Trials in OncologyOTHER | 1 | Apr 23, 2025 | clinicaltrials |
| NCT04174599 | Study to Compare the Efficacy and Safety of F-627 and GRAN® | completed | Phase 3 | 242 | EVIVE BiotechnologyINDUSTRY | 1 | Apr 20, 2025 | clinicaltrials |
| NCT05555706 | Study of B013 and Nab-Paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer | completed | Phase 2 / Phase 3 | 62 | Shanghai Jiaolian Drug Research and Development Co., LtdINDUSTRY | 1 | Apr 15, 2025 | clinicaltrials |
| NCT03753776 | Phase III Trial Evaluating Radium Bromatum Homeopathic Treatment Efficacy on Radiodermatitis Prevention and Treatment for Breast Cancer Women(HOMEORAD) | completed | Phase 3 | 232 | Centre Hospitalier Universitaire de Saint EtienneOTHER | 1 | Apr 9, 2025 | clinicaltrials |
| NCT01779206 | ADAPT - Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer(ADAPT) | completed | Phase 2 / Phase 3 | 4,936 | Women's Cancer Study Group GmbHOTHER | 1 | Apr 8, 2025 | clinicaltrials |
| NCT04193722 | The Effect of Hyperbaric OxygeN Therapy on brEast Cancer Patients With Late Radiation toxicitY - UMBRELLA HONEY Trial(HONEY) | completed | Phase 3 | 189 | UMC UtrechtOTHER | 1 | Apr 3, 2025 | clinicaltrials |
| NCT00490139 | ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D(ALTTO) | completed | Phase 3 | 8,381 | Novartis PharmaceuticalsINDUSTRY | 44 | Mar 21, 2025 | clinicaltrials |
| NCT00667251 | Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer | completed | Phase 3 | 652 | Novartis PharmaceuticalsINDUSTRY | 21 | Mar 21, 2025 | clinicaltrials |
| NCT01160211 | A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer | completed | Phase 3 | 369 | Novartis PharmaceuticalsINDUSTRY | 29 | Mar 7, 2025 | clinicaltrials |
| NCT01958021 | Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer(MONALEESA-2) | completed | Phase 3 | 668 | Novartis PharmaceuticalsINDUSTRY | 29 | Mar 7, 2025 | clinicaltrials |
| NCT01781338 | Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer(ADAPT) | completed | Phase 2 / Phase 3 | 4,936 | Women's Cancer Study Group GmbHOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT02214381 | A Prospective, Multicenter, Open-label 12 Week Neoadjuvant Phase II Trial Optimizing Taxane Therapy in Elderly Patients With Low Response | completed | Phase 3 | 80 | Women's Cancer Study Group GmbHOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT00949598 | Letrozole or Tamoxifen Citrate in Treating Older Postmenopausal Women Undergoing Surgery for Breast Cancer | completed | Phase 3 | 177 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Feb 13, 2025 | clinicaltrials |
| NCT02437318 | Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.(SOLAR-1) | completed | Phase 3 | 572 | Novartis PharmaceuticalsINDUSTRY | 31 | Feb 13, 2025 | clinicaltrials |
| NCT01084876 | Demonstrate Efficacy and Safety of Metastatic Breast Cancer(Compare) | completed | Phase 3 | 475 | CelltrionINDUSTRY | 1 | Feb 11, 2025 | clinicaltrials |
| NCT01573442 | Testosterone in Treating Postmenopausal Patients With Arthralgia Caused by Adjuvant Aromatase Inhibitor Treatment | completed | Phase 3 | 227 | Alliance for Clinical Trials in OncologyOTHER | 2 | Jan 28, 2025 | clinicaltrials |
| NCT04109066 | Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer(CheckMate 7FL) | completed | Phase 3 | 521 | Bristol-Myers SquibbINDUSTRY | 32 | Jan 8, 2025 | clinicaltrials |
| NCT00002644 | Tamoxifen for the Prevention of Breast Cancer in High-Risk Women(IBIS-1) | completed | Phase 3 | 7,154 | Queen Mary University of LondonOTHER | 1 | Dec 11, 2024 | clinicaltrials |
| NCT02819518 | Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355) | completed | Phase 3 | 882 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Nov 27, 2024 | clinicaltrials |
| NCT01740427 | A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2) | completed | Phase 3 | 666 | PfizerINDUSTRY | 18 | Nov 14, 2024 | clinicaltrials |
| NCT03013504 | A Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of HD201 to Herceptin® in HER2+ Early Breast Cancer Patients(TROIKA) | completed | Phase 3 | 503 | Prestige Biopharma LimitedINDUSTRY | 13 | Nov 6, 2024 | clinicaltrials |
| NCT00115713 | Effects of Aerobic Exercise Versus Weight Training in Breast Cancer Survivors During Chemotherapy | completed | Phase 3 | 240 | University of AlbertaOTHER | 1 | Nov 5, 2024 | clinicaltrials |
| NCT00221221 | Physical Activity Promotion in Breast Cancer Survivors | completed | Phase 2 / Phase 3 | 300 | University of AlbertaOTHER | 1 | Nov 5, 2024 | clinicaltrials |
| NCT03726879 | A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer(IMpassion050) | completed | Phase 3 | 454 | Hoffmann-La RocheINDUSTRY | 12 | Nov 5, 2024 | clinicaltrials |
| NCT03901339 | Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer(TROPiCS-02) | completed | Phase 3 | 543 | Gilead SciencesINDUSTRY | 9 | Oct 21, 2024 | clinicaltrials |
| NCT05054751 | GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer | completed | Phase 3 | 275 | Genor Biopharma Co., Ltd.INDUSTRY | 1 | Oct 10, 2024 | clinicaltrials |
| NCT01224678 | Vitamin D and Breast Cancer Biomarkers in Female Patients | completed | Phase 3 | 300 | Alliance for Clinical Trials in OncologyOTHER | 1 | Oct 8, 2024 | clinicaltrials |
| NCT02028507 | Phase III Palbociclib With Endocrine Therapy vs. Capecitabine in HR+/HER2- MBC With Resistance to Aromatase Inhibitors(PEARL) | completed | Phase 3 | 693 | Spanish Breast Cancer Research GroupOTHER | 4 | Sep 25, 2024 | clinicaltrials |
| NCT00365105 | Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer | completed | Phase 3 | 261 | Radiation Therapy Oncology GroupNETWORK | 1 | Sep 20, 2024 | clinicaltrials |
| NCT00072462 | Adjuvant Tamoxifen Compared With Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ(IBIS-II DCIS) | completed | Phase 3 | 2,980 | Queen Mary University of LondonOTHER | 14 | Sep 19, 2024 | clinicaltrials |
| NCT00220792 | Group Therapy for Primary Breast Cancer | completed | Phase 3 | 480 | Stanford UniversityOTHER | 1 | Aug 26, 2024 | clinicaltrials |
| NCT00725374 | A Study to Investigate the Effects of Tibolone (Livial®) on Breast Tissue in Postmenopausal Women With Breast Cancer (Study 32971)(P06469)(STEM) | completed | Phase 3 | 102 | Organon and CoINDUSTRY | 0 | Aug 15, 2024 | clinicaltrials |
| NCT04799249 | Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)(PRESERVE 2) | completed | Phase 3 | 194 | G1 Therapeutics, Inc.INDUSTRY | 11 | Aug 1, 2024 | clinicaltrials |
| NCT04957212 | Comparing Efficacy and Safety Between Pertuzumab® and Perjeta® in Neoadjuvant Treatment of HER2+ Breast Cancer | completed | Phase 3 | 214 | CinnagenINDUSTRY | 1 | Jul 26, 2024 | clinicaltrials |
| NCT05283837 | A Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Immunogenicity of Test Pertuzumab (ZRC-3277, Cadila Healthcare Ltd.,) | completed | Phase 3 | 268 | Zydus Lifesciences LimitedINDUSTRY | 1 | Jul 18, 2024 | clinicaltrials |
| NCT00673335 | Letrozole in Preventing Breast Cancer in Postmenopausal Women With a BRCA1 or BRCA2 Mutation(LIBER) | completed | Phase 3 | 170 | UNICANCEROTHER | 1 | Jul 1, 2024 | clinicaltrials |
| NCT03425656 | Comparing Efficacy and Safety of AryoGen Pharmed Biosimilar Trastuzumab (AryoTrust) Versus Herceptin® in Breast Cancer | completed | Phase 3 | 108 | AryoGen Pharmed Co.INDUSTRY | 1 | Jun 28, 2024 | clinicaltrials |
| NCT03493854 | A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer(FeDeriCa) | completed | Phase 3 | 500 | Hoffmann-La RocheINDUSTRY | 19 | Jun 26, 2024 | clinicaltrials |
| NCT03084237 | Compare Efficacy, Safety and Immunogenicity of HLX02 and Herceptin in Previously Untreated HER2 +Overexpressing Metastatic Breast Cancer | completed | Phase 3 | 652 | Shanghai Henlius BiotechINDUSTRY | 3 | May 17, 2024 | clinicaltrials |
| NCT03324802 | Hypofractionated Radiation Therapy in Preventing Recurrence in Patients With Breast Cancer After Surgery | completed | Phase 3 | 107 | Mayo ClinicOTHER | 1 | May 2, 2024 | clinicaltrials |
| NCT01468883 | The Treatment of Stage I and II Carcinoma of the Breast With Mastectomy and Axillary Dissection Versus Excisional Biopsy, Axillary Dissection, and Definitive Irradiation | completed | Phase 3 | 256 | National Cancer Institute (NCI)NIH | 1 | Apr 26, 2024 | clinicaltrials |
| NCT05629949 | A Multicenter, Double-blind, Randomized, Parallel-group, Phase III Study of the Efficacy and Safety of QL1701 Plus Docetaxel Versus Herceptin® Plus Docetaxel as First Line Therapy in Patients With HER2-positive Metastatic Breast Cancer | completed | Phase 3 | 474 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 23, 2024 | clinicaltrials |
| NCT01942135 | Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3) | completed | Phase 3 | 521 | PfizerINDUSTRY | 17 | Apr 4, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Jul 14, 2025source: clinicaltrials